| acute myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| DEDICATION, 2008 | vs bare-metal stent | MACE 0.62 [0.40; 0.97] target-vessel revascularization 0.39 [0.22; 0.68] 2 yr TLR 0.37 [0.22; 0.61] 2 yr MACE 0.63 [0.43; 0.93] | | MACE at 5yr 0.81 [0.57; 1.16] 2 yr MI (all) 0.60 [0.22; 1.63] all cause mortality 2.00 [0.87; 4.61] cardiac death 2.60 [0.94; 7.21] Stent thrombosis (any, end of follow-up) 0.88 [0.32; 2.38] 4 yr TLR 0.67 [0.39; 1.16] 4 yr MI 1.49 [0.72; 3.09] 4 yr stent thrombosis 1.98 [0.67; 5.85] 2 yr Death (all cause) 1.64 [0.97; 2.80] | | PASEO, 2009 | vs bare-metal stent | | | |
| Trial | Treatments | Patients | Method |
|---|
| DEDICATION, 2008 | DES currently used with or without distal protection (n=313) vs. BMS with or without distal protection
(n=313) patients were also randomized to treatment with or without distal protection using a filter wire system (factorial design)
| patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction
| open Factorial plan Sample size: 313/313 Primary endpoint: loss of the lumen diameter FU duration: 8 mo (15 mo, 3y)
| | PASEO, 2009 | paclitaxel-eluting stents and sirolimus-eluting stents (n=180) vs. bare metal stent (n=90) 3 arms : SES, PES, BM | patients with ST-elevation myocardial infarction within 12 hours from symptom onset | open Parallel groups Sample size: 180/90 Primary endpoint: TLR 1 year FU duration: 4.3 years |
|
| coronary artery disease | All results are NS for efficacy inferior to CABG in terms of 5 year cardiovascular events in FREEDOM, 2012 inferior to CABG in terms of long term death in FREEDOM, 2012 inferior to CABG in terms of long term cardiovascular events in FREEDOM, 2012 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| FREEDOM, 2012 | vs CABG | | 5 year cardiovascular events 1.36 [1.12; 1.65] long term death 1.36 [1.05; 1.77] long term cardiovascular events 1.39 [1.14; 1.68] | 5 year death 1.40 [0.99; 1.97] Death 1.5 to 2 years 1.08 [0.76; 1.53] Events 2 years 1.11 [0.87; 1.42] | | Hong, 2005 | vs CABG | | | | | DEDICATION, 2008 | vs CABG | MACE 0.62 [0.40; 0.97] target-vessel revascularization 0.39 [0.22; 0.68] 2 yr TLR 0.37 [0.22; 0.61] 2 yr MACE 0.63 [0.43; 0.93] | | MACE at 5yr 0.81 [0.57; 1.16] 2 yr MI (all) 0.60 [0.22; 1.63] all cause mortality 2.00 [0.87; 4.61] cardiac death 2.60 [0.94; 7.21] Stent thrombosis (any, end of follow-up) 0.88 [0.32; 2.38] 4 yr TLR 0.67 [0.39; 1.16] 4 yr MI 1.49 [0.72; 3.09] 4 yr stent thrombosis 1.98 [0.67; 5.85] 2 yr Death (all cause) 1.64 [0.97; 2.80] | | GENIUS-STEMI, 2009 | vs CABG | | | MACE 2.00 [NaN; NaN] MI -∞ [NaN; NaN] target lesion revascularisation (TLR ) -∞ [NaN; NaN] stent thrombosis (ARC) ∞ [NaN; ∞] | | PASEO, 2009 | vs CABG | | | | | Boudriot, 2008 | vs CABG | | | all cause mortality 0.39 [0.06; 2.46] target-vessel revascularization 2.33 [0.77; 7.05] |
| Trial | Treatments | Patients | Method |
|---|
| FREEDOM, 2012 | percutaneous coronary stenting (n=953) vs. CABG (n=947) | patients with diabetes and multivessel coronary artery disease | open Parallel groups Sample size: 953/947 Primary endpoint: death, MI, stroke FU duration: 3.8 yrs (median) | | Hong, 2005 | drug-eluting stents (n=119) vs. invasive direct coronary artery bypass (MIDCAB) surgery (n=70) | proximal left anterior descending (LAD) coronary artery stenosis | open Parallel groups Sample size: 119/70 Primary endpoint: FU duration: 9 months | | DEDICATION, 2008 | DES currently used with or without distal protection (n=313) vs. BMS with or without distal protection
(n=313) patients were also randomized to treatment with or without distal protection using a filter wire system (factorial design)
| patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction
| open Factorial plan Sample size: 313/313 Primary endpoint: loss of the lumen diameter FU duration: 8 mo (15 mo, 3y)
| | GENIUS-STEMI, 2009 | endothelial progenitor cell capture stent (n=50) vs. cobalt chromium stent (n=50) | patients with ST-elevation myocardial infarction | NA Parallel groups Sample size: 50/50 Primary endpoint: MACE FU duration: 6 months | | PASEO, 2009 | paclitaxel-eluting stents and sirolimus-eluting stents (n=180) vs. bare metal stent (n=90) 3 arms : SES, PES, BM | patients with ST-elevation myocardial infarction within 12 hours from symptom onset | open Parallel groups Sample size: 180/90 Primary endpoint: TLR 1 year FU duration: 4.3 years | | Boudriot, 2008 | DES (n=83) vs. CABG (n=84) | | open Parallel groups Sample size: 83/84 Primary endpoint: FU duration: 12 months |
|
| stable angina | All results are NS for efficacy inferior to CABG in terms of 5 year cardiovascular events in FREEDOM, 2012 inferior to CABG in terms of long term death in FREEDOM, 2012 inferior to CABG in terms of long term cardiovascular events in FREEDOM, 2012 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| FREEDOM, 2012 | vs CABG | | 5 year cardiovascular events 1.36 [1.12; 1.65] long term death 1.36 [1.05; 1.77] long term cardiovascular events 1.39 [1.14; 1.68] | 5 year death 1.40 [0.99; 1.97] Death 1.5 to 2 years 1.08 [0.76; 1.53] Events 2 years 1.11 [0.87; 1.42] | | Hong, 2005 | vs CABG | | | | | Boudriot, 2008 | vs CABG | | | all cause mortality 0.39 [0.06; 2.46] target-vessel revascularization 2.33 [0.77; 7.05] |
| Trial | Treatments | Patients | Method |
|---|
| FREEDOM, 2012 | percutaneous coronary stenting (n=953) vs. CABG (n=947) | patients with diabetes and multivessel coronary artery disease | open Parallel groups Sample size: 953/947 Primary endpoint: death, MI, stroke FU duration: 3.8 yrs (median) | | Hong, 2005 | drug-eluting stents (n=119) vs. invasive direct coronary artery bypass (MIDCAB) surgery (n=70) | proximal left anterior descending (LAD) coronary artery stenosis | open Parallel groups Sample size: 119/70 Primary endpoint: FU duration: 9 months | | Boudriot, 2008 | DES (n=83) vs. CABG (n=84) | | open Parallel groups Sample size: 83/84 Primary endpoint: FU duration: 12 months |
|
